Science 37 has created a patient experience while introducing native support for iOS and Android operating systems. With this development, patients can not only participate from the comfort of their own home, but they can also do it with the familiarity of their own smartphones.
Using their own devices (BYOD), patients can learn more about a study, provide consent, schedule and participate in study visits, complete assessments, and communicate directly with the Science 37 study team and investigators, all through a single platform.
The intuitive, cloud-based platform also integrates workflow and processes for physician investigators, mobile nurses, and coordinators across the entire trial life cycle. Combining these advantages with native support for iOS and Android further enhances the company’s ability to deploy its services globally.
Chris Ceppi, chief product officer of Science 37 says, “The fully integrated mobile capabilities we’re introducing enable a patient experience that sets a new standard for clinical studies.”
In addition to the platform, Science 37 has also conducted more fully decentralized, interventional clinical trials-all the way from protocol design to database lock. Coupled with its telemedicine and home health network, Science 37 enables coverage around the world.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.